Janus Henderson Group
CMPX icon

Janus Henderson Group’s Compass Therapeutics CMPX Stock Holding History

Janus Henderson Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$294K Buy
+55,600
New +$321K ﹤0.01% 2222
2024
Q4 		– Sell
-1,843,286
Closed -$3.36M – 2536
2024
Q3 		$3.36M Sell
1,843,286
-3,373,056
-65% -$4.2M ﹤0.01% 1056
2024
Q2 		$5.76M Sell
5,216,342
-1,276,558
-20% -$1.86M ﹤0.01% 797
2024
Q1 		$12.8M Sell
6,492,900
-54,331
-0.8% -$93.9K 0.01% 642
2023
Q4 		$10.2M Sell
6,547,231
-113,407
-2% -$196K 0.01% 666
2023
Q3 		$13.1M Buy
6,660,638
+441,897
+7% +$1.09M 0.01% 610
2023
Q2 		$19.7M Buy
6,218,741
+214,268
+4% +$673K 0.01% 560
2023
Q1 		$19.6M Buy
6,004,473
+65,183
+1% +$256K 0.01% 583
2022
Q4 		$29.8M Sell
5,939,290
-1,106,670
-16% -$4.41M 0.02% 484
2022
Q3 		$16.1M Buy
7,045,960
+3,698,789
+111% +$10.2M 0.01% 721
2022
Q2 		$8.8M Buy
3,347,171
+153,877
+5% +$334K 0.01% 718
2022
Q1 		$4.33M Buy
3,193,294
+1,720,683
+117% +$3.56M ﹤0.01% 1041
2021
Q4 		$4.7M Buy
+1,472,611
New +$4.88M ﹤0.01% 1078

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group's CMPX Position: Q1 2026 in Review

Janus Henderson Group opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 55,600 shares worth $294K. The stake represents ﹤0.01% of the portfolio and ranks #2222 among its holdings. This is a return to the name: Janus Henderson Group previously reported a position in CMPX as recently as Q3 2024.

Janus Henderson Group first reported a position in CMPX in Q4 2021 and has held it in 13 quarters since. The position peaked at $29.8M in Q4 2022. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Janus Henderson Group held 55,600 shares of Compass Therapeutics worth $294K as of Q1 2026.
  • Compass Therapeutics was a new Janus Henderson Group position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2222 holding.
  • Janus Henderson Group first reported a position in Compass Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Janus Henderson Group's Compass Therapeutics position peaked at $29.8M in Q4 2022.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.